The company had posted a net profit after tax, minority interest and share of profit of joint ventures of Rs. 453.55 crore for the same period year ago, Aurobindo Pharma said in a BSE filing.
Aurobindo Pharma on Monday reported 33.53 per cent rise in consolidated net profit to Rs. 605.64 crore for the quarter ending September mainly on account of robust formulation sales.
The company had posted a net profit after tax, minority interest and share of profit of joint ventures of Rs. 453.55 crore for the same period year ago, Aurobindo Pharma said in a BSE filing.
Consolidated total income from operations also rose to Rs. 3,775.45 crore for the quarter under consideration as against Rs. 3,365.11 crore for the corresponding period of the previous fiscal.
Commenting on the results, Aurobindo Pharma Managing Director N Govindarajan said: "We witnessed satisfactory quarter on a year-on-year basis with enhanced cost efficiencies."
The company continues to invest for long term growth by creating niche, differentiated products, he added.
The formulations business contributed 80 per cent to the total revenues and witnessed 12.4 per cent y-o-y growth during the quarter. The broad-based growth across all the markets led to an increase in the formulations revenue, Aurobindo Pharma said.
During the second quarter of 2016-17, the company filed nine abbreviated new drug applications (ANDAs) with USFDA including six in the oral category and three in the injectable category, it added.
Read originally published article: http://bit.ly/2eUZj6I
Aurobindo Pharma on Monday reported 33.53 per cent rise in consolidated net profit to Rs. 605.64 crore for the quarter ending September mainly on account of robust formulation sales.
The company had posted a net profit after tax, minority interest and share of profit of joint ventures of Rs. 453.55 crore for the same period year ago, Aurobindo Pharma said in a BSE filing.
Consolidated total income from operations also rose to Rs. 3,775.45 crore for the quarter under consideration as against Rs. 3,365.11 crore for the corresponding period of the previous fiscal.
Commenting on the results, Aurobindo Pharma Managing Director N Govindarajan said: "We witnessed satisfactory quarter on a year-on-year basis with enhanced cost efficiencies."
The company continues to invest for long term growth by creating niche, differentiated products, he added.
The formulations business contributed 80 per cent to the total revenues and witnessed 12.4 per cent y-o-y growth during the quarter. The broad-based growth across all the markets led to an increase in the formulations revenue, Aurobindo Pharma said.
During the second quarter of 2016-17, the company filed nine abbreviated new drug applications (ANDAs) with USFDA including six in the oral category and three in the injectable category, it added.
Read originally published article: http://bit.ly/2eUZj6I
No comments:
Post a Comment